Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 1074050

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 1074050

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2032

PUBLISHED:
PAGES: 117 Pages
DELIVERY TIME: 1-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4750
PDF (Site License)
USD 9500
PDF (Global License)
USD 14250

Add to Cart

DelveInsight's, 'Acute Respiratory Distress Syndrome - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acute Respiratory Distress Syndrome Disease Understanding

ARDS is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible. It is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury which leads to fluid build-up inside the tiny air sacs of the lungs, and surfactant breakdown.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.

Usually, the first symptom of ARDS is shortness of breath, cough, and fever. Other signs and symptoms of ARDS are low blood oxygen, rapid breathing, clicking, bubbling, or rattling sounds in the lungs when breathing.

ARDS is generally characterized by three stages such as exudative stage, fibroproliferative (or proliferative) stage, resolution, and recovery stage. The exudative stage is the accumulation of protein, excessive fluid and inflammatory cells in the alveoli occur in the exudative stage. This phase usually is seen within the first 2 to 4 days after the onset of lung injury. Fibroproliferative (or proliferative) stage is the proliferation of connective tissue and other structural elements in the lungs in response to the initial lung injury. The chances of a patient having pneumonia sepsis and rupture of the lungs are very high in this stage. Resolution and Recovery are in this stage, the lung reorganizes and recovers. During this stage, lung function may continue to improve in patients. The fourth phase of ARDS is also seen according to some experts in which when some patients due to acute illness have continued health problems while some may experience anxiety, depression, and flashback memories of their critical illness, which are very similar to post-traumatic stress disorder. This stage is still an area under research.

Acute Respiratory Distress Syndrome Diagnosis

Early recognition of ARDS is important for the timely initiation of lung-protective ventilation strategies. Even after attempts to improve the definition of the disease, ARDS remains under-recognized by clinicians. Oftentimes, when a diagnosis is made, it has been after a significant delay. The rate of under-diagnosis is reported to be as high as 40%, with higher rates of diagnosis with increasing disease severity. ARDS is a syndrome with several different clinical criteria that must be fulfilled; however, none of these data points is particularly precise. The current clinical criteria have low specificity, for example, 63% for the Berlin definition to identify DAD at autopsy. At present, no biomarker is present to aid in the diagnosis, and this is now an area of much active research.

Chest X-rays for the diagnosis of ARDS have relatively low sensitivity and specificity of approximately 70% when compared to CT scans. CXR performs better when the infiltrates are diffuse or patchy as opposed to focal. The use of CT scans and other imaging techniques in the diagnosis and management of ARDS has become increasingly important. Lung ultrasound is another modality that can be used as a bedside tool to facilitate the diagnosis of ARDS.

Continued in the report…..

Acute Respiratory Distress Syndrome Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Acute Respiratory Distress Syndrome, Severity-specific Cases of Acute Respiratory Distress Syndrome, and Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors scenario of ARDS in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Acute Respiratory Distress Syndrome Detailed Epidemiology Segmentation

  • In 2021, the total incident cases of ARDS were estimated to be 1,088,015 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 1.5% during the study period (2019-2032).
  • Among the 7MM, the United States has the highest number of incident cases of ARDS with approximately 630,584 cases in 2021.
  • Assessments as per DelveInsight's, analysts show that in terms of severity-specific incidence, a similar trend is observed in all countries, with a majority of the cases pointing to moderate ARDS, except France, where severe cases of ARDS accounted for a maximum patient population.
  • Generally, among the 7MM countries, the primary risk factor associated with the highest number of incident cases of ARDS was pneumonia, except for the United Kingdom, where sepsis was the primary risk factor for ARDS
  • In the United States, there were a total of 189,175, 293,852, and 147,557 severity-specific cases of mild, moderate, and severe ARDS respectively, in 2021. Assessments as per DelveInsight's, analysts show that the majority of cases of ARDS are of moderate ARDS, followed by mild and severe and this is subject to change due to a rapid increase in the coming years.
  • Among the EU-5, Germany had the highest total incident population of ARDS with 193,828 cases, followed by France (73,541 cases), and Italy with 55,522 cases in 2021. On the other hand, Spain (31,286 cases) had the lowest incident population for 2021.
  • In 2021, Japan had approximately 69,628 total incident cases of ARDS which are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019-2032).

Scope of the Report:

  • The report covers the descriptive overview of Acute Respiratory Distress Syndrome, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of Acute Respiratory Distress Syndrome.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for the 7MM, Total Incident Cases of Acute Respiratory Distress Syndrome, Severity-specific Cases of Acute Respiratory Distress Syndrome, and Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors.

Report Highlights:

  • 11-Year Forecast of Acute Respiratory Distress Syndrome
  • The 7MM Coverage
  • Total Incident Cases of Acute Respiratory Distress Syndrome
  • Severity-specific Cases of Acute Respiratory Distress Syndrome
  • Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors

Key Questions Answered

  • What are the disease risk and burdens of Acute Respiratory Distress Syndrome?
  • What is the historical Acute Respiratory Distress Syndrome patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Acute Respiratory Distress Syndrome at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population with Acute Respiratory Distress Syndrome?
  • Out of the above-mentioned countries, which country would have the highest incident population of Acute Respiratory Distress Syndrome during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

The Acute Respiratory Distress Syndrome report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Acute Respiratory Distress Syndrome epidemiology forecast.
  • The Acute Respiratory Distress Syndrome epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
  • The Acute Respiratory Distress Syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Product Code: DIEI0462

Table of Contents

1. Key Insights

2. Report Introduction

3. Acute Respiratory Distress Syndrome Epidemiology Overview at a Glance

  • 3.1. Patient Share (%) Distribution of Acute Respiratory Distress Syndrome in 2019
  • 3.2. Patient Share (%) Distribution of Acute Respiratory Distress Syndrome in 2032

4. Executive Summary of Acute Respiratory Distress Syndrome Epidemiology

5. Disease Background and Overview

  • 5.1. Introduction of Acute Respiratory Distress Syndrome
    • 5.1.1. Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
    • 5.1.2. Development of Berlin Definition of ARDS
    • 5.1.3. Problems with the AECC definition and subsequent Berlin definition of ARDS
  • 5.2. Causes and Risk Factors
    • 5.2.1. Risk Factors of Acute Respiratory Distress Syndrome
      • 5.2.1.1. ARDS associated with Covid-19
  • 5.3. Pathophysiology of Acute Respiratory Distress Syndrome
  • 5.4. Stages of Acute Respiratory Distress Syndrome
  • 5.5. Ventilator-Induced Lung Injury (VILI)
  • 5.6. Diagnosis of Acute Respiratory Distress Syndrome
    • 5.6.1. Differential Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Methodology of Epidemiology
  • 6.3. Assumptions and Rationale: 7MM
    • 6.3.1. The United States
    • 6.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)
    • 6.3.3. Japan
  • 6.4. Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM
  • 6.5. The United States
    • 6.5.1. Total Incident Cases of Acute Respiratory Distress Syndrome in the United States
    • 6.5.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in the United States
    • 6.5.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the United States
  • 6.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
    • 6.6.1. Germany
      • 6.6.1.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Germany
      • 6.6.1.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany
      • 6.6.1.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany
    • 6.6.2. France
      • 6.6.2.1. Total Incident Cases of Acute Respiratory Distress Syndrome in France
      • 6.6.2.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in France
      • 6.6.2.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France
    • 6.6.3. Italy
      • 6.6.3.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Italy
      • 6.6.3.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy
      • 6.6.3.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy
    • 6.6.4. Spain
      • 6.6.4.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Spain
      • 6.6.4.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain
      • 6.6.4.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain
    • 6.6.5. The United Kingdom
      • 6.6.5.1. Total Incident Cases of Acute Respiratory Distress Syndrome in the UK
      • 6.6.5.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK
      • 6.6.5.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK
  • 6.7. Japan
    • 6.7.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Japan
    • 6.7.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan
    • 6.7.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan

7. Patient Journey

8. Key Opinion Leaders' Views

9. Appendix

  • 9.1. Bibliography
  • 9.2. Acronyms and Abbreviations

10. Report Methodology

11. DelveInsight Capabilities

11. Disclaimer

13. About DelveInsight

Product Code: DIEI0462

List of Tables

  • Table 1: Summary of Acute Respiratory Distress Syndrome Epidemiology (2019-2032)
  • Table 2: Definition of Acute Respiratory Distress Syndrome
  • Table 3: American European Consensus Conference Criteria for Acute Lung Injury (ALI) and the Acute Respiratory Distress Syndrome (ARDS)
  • Table 4: Berlin Definition of Mild, Moderate, and Severe Acute Respiratory Distress Syndrome (ARDS)
  • Table 5: Factors That Distinguish ARDS, CHF, and Pneumonia
  • Table 6: Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM (2019-2032)
  • Table 7: Total Incident Cases of Acute Respiratory Distress Syndrome in the US (2019-2032)
  • Table 8: Severity-specific Cases of Acute Respiratory Distress Syndrome in the US (2019-2032)
  • Table 9: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the US (2019-2032)
  • Table 10: Total Incident Cases of Acute Respiratory Distress Syndrome in Germany (2019-2032)
  • Table 11: Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany (2019-2032)
  • Table 12: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany (2019-2032)
  • Table 13: Total Incident Cases of Acute Respiratory Distress Syndrome in France (2019-2032)
  • Table 14: Severity-specific Cases of Acute Respiratory Distress Syndrome in France (2019-2032)
  • Table 15: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France (2019-2032)
  • Table 16: Total Incident Cases of Acute Respiratory Distress Syndrome in Italy (2019-2032)
  • Table 17: Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy (2019-2032)
  • Table 18: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy (2019-2032)
  • Table 19: Total Incident Cases of Acute Respiratory Distress Syndrome in Spain (2019-2032)
  • Table 20: Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain (2019-2032)
  • Table 21: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain (2019-2032)
  • Table 22: Total Incident Cases of Acute Respiratory Distress Syndrome in the UK (2019-2032)
  • Table 23: Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK (2019-2032)
  • Table 24: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK (2019-2032)
  • Table 25: Total Incident Cases of Acute Respiratory Distress Syndrome in Japan (2019-2032)
  • Table 26: Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan (2019-2032)
  • Table 27: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan (2019-2032)

List of Figures

  • Figure 1: Risk factors of Acute Respiratory Distress Syndrome
  • Figure 2: A simplified model of the pathogenesis of Acute Respiratory Distress syndrome
  • Figure 3: Effects of Mast Cell Activation
  • Figure 4: Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM (2019-2032)
  • Figure 5: Incident Cases of Acute Respiratory Distress Syndrome in the US (2019-2032)
  • Figure 6: Severity-specific Cases of Acute Respiratory Distress Syndrome in the US (2019-2032)
  • Figure 7: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the US (2019-2032)
  • Figure 8: Total Incident Cases of Acute Respiratory Distress Syndrome in Germany (2019-2032)
  • Figure 9: Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany (2019-2032)
  • Figure 10: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany (2019-2032)
  • Figure 11: Total Incident Cases of Acute Respiratory Distress Syndrome in France (2019-2032)
  • Figure 12: Severity-specific Cases of Acute Respiratory Distress Syndrome in France (2019-2032)
  • Figure 13: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France (2019-2032)
  • Figure 14: Total Incident Cases of Acute Respiratory Distress Syndrome in Italy (2019-2032)
  • Figure 15: Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy (2019-2032)
  • Figure 16: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy (2019-2032)
  • Figure 17: Total Incident Cases of Acute Respiratory Distress Syndrome in Spain (2019-2032)
  • Figure 18: Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain (2019-2032)
  • Figure 19: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain (2019-2032)
  • Figure 20: Total Incident Cases of Acute Respiratory Distress Syndrome in the UK (2019-2032)
  • Figure 21: Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK (2019-2032)
  • Figure 22: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK (2019-2032)
  • Figure 23: Total Incident Cases of Acute Respiratory Distress Syndrome in Japan (2019-2032)
  • Figure 24: Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan (2019-2032)
  • Figure 25: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan (2019-2032)
  • Figure 26: Patient Journey
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!